The TYMP-targeting drug TAS-102, a trifluridine-tipiracil hydrochloride mixture, is currently approved for treating advanced colorectal cancer and gastric cancer [49, 50] after at least two lines of chemotherapy [51–54]. Here, TYMP is linked to colorectal cancer.